...
首页> 外文期刊>The Journal of biological chemistry >β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models
【24h】

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

机译:β2肾上腺素能受体,蛋白激酶A(PKA)和C-JUN N-末端激酶(JNK)信号通路在阿尔茨海默病模型中介导TAU病理

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Alzheimer disease (AD) is characterized by neurodegeneration marked by loss of synapses and spines associated with hyperphosphorylation of tau protein. Accumulating amyloid β peptide (Aβ) in brain is linked to neurofibrillary tangles composed of hyperphosphorylated tau in AD. Here, we identify β2-adrenergic receptor (β2AR) that mediates Aβ-induced tau pathology. In the prefrontal cortex (PFC) of 1-year-old transgenic mice with human familial mutant genes of presenilin 1 and amyloid precursor protein (PS1/APP), the phosphorylation of tau at Ser-214 Ser-262 and Thr-181, and the protein kinases including JNK, GSK3α/β, and Ca2+/calmodulin-dependent protein kinase II is increased significantly. Deletion of the β2AR gene in PS1/APP mice greatly decreases the phosphorylation of these proteins. Further analysis reveals that in primary PFC neurons, Aβ signals through a β2AR-PKA-JNK pathway, which is responsible for most of the phosphorylation of tau at Ser-214 and Ser-262 and a significant portion of phosphorylation at Thr-181. Aβ also induces a β2AR-dependent arrestin-ERK1/2 activity that does not participate in phosphorylation of tau. However, inhibition of the activity of MEK, an upstream enzyme of ERK1/2, partially blocks Aβ-induced tau phosphorylation at Thr-181. The density of dendritic spines and synapses is decreased in the deep layer of the PFC of 1-year-old PS1/APP mice, and the mice exhibit impairment of learning and memory in a novel object recognition paradigm. Deletion of the β2AR gene ameliorates pathological effects in these senile PS1/APP mice. The study indicates that β2AR may represent a potential therapeutic target for preventing the development of AD.
机译:阿尔茨海默病(Ad)的特征在于通过与Tau蛋白质的超磷酸化相关的突触和刺痛而标记的神经变性。脑内淀粉样蛋白β肽(Aβ)与AD中的高磷酸化陶器组成的神经纤维缠结有关。在此,我们鉴定培养Aβ诱导的TAU病理学的β2-肾上腺素能受体(β2AR)。在具有Presenilin 1和淀粉样蛋白前体蛋白(PS1 / APP)的人类家族突变基因的1岁转基因小鼠的前额叶皮质(PFC),SER-214 SER-262和THR-181的TAU磷酸化,包括JNK,GSK3α/β和Ca2 + /钙调蛋白依赖性蛋白激酶II的蛋白激酶显着增加。 PS1 / APP小鼠中β2AR基因的缺失大大降低了这些蛋白质的磷酸化。进一步的分析表明,在初级PFC神经元中,通过β2AR-PKA-JNK途径的Aβ信号,其负责Ser-214和Ser-262的大部分Tau的磷酸化以及Thr-181的大部分磷酸化。 Aβ还诱导β2AR依赖性抑制素-ERK1 / 2活性,其不参与TAU的磷酸化。然而,抑制MEK的活性,ERK1 / 2的上游酶,部分地阻断THR-181的Aβ诱导的TAU磷酸化。在1岁的PS1 / APP小鼠PFC的深层中,树突刺和突触的密度减少,小鼠在新的对象识别范式中表现出学习和记忆的损害。 β2AR基因的缺失改善了这些老年PS1 / APP小鼠的病理效应。该研究表明,β2AR可以代表防止广告发育的潜在治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号